NewAmsterdam Begin Period Cash Flow vs Ev To Free Cash Flow Analysis

NAMSW Stock

8.90 0.12 1.33%

NewAmsterdam Pharma financial indicator trend analysis is infinitely more than just investigating NewAmsterdam Pharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NewAmsterdam Pharma is a good investment. Please check the relationship between NewAmsterdam Pharma Begin Period Cash Flow and its Ev To Free Cash Flow accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NewAmsterdam Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.

Begin Period Cash Flow vs Ev To Free Cash Flow

Begin Period Cash Flow vs Ev To Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NewAmsterdam Pharma Begin Period Cash Flow account and Ev To Free Cash Flow. At this time, the significance of the direction appears to have strong relationship.

The correlation between NewAmsterdam Pharma's Begin Period Cash Flow and Ev To Free Cash Flow is 0.77. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Ev To Free Cash Flow in the same time period over historical financial statements of NewAmsterdam Pharma, assuming nothing else is changed. The correlation between historical values of NewAmsterdam Pharma's Begin Period Cash Flow and Ev To Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of NewAmsterdam Pharma are associated (or correlated) with its Ev To Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Free Cash Flow has no effect on the direction of Begin Period Cash Flow i.e., NewAmsterdam Pharma's Begin Period Cash Flow and Ev To Free Cash Flow go up and down completely randomly.

Correlation Coefficient

0.77

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Ev To Free Cash Flow

A valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued.

Most indicators from NewAmsterdam Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NewAmsterdam Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NewAmsterdam Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.At this time, NewAmsterdam Pharma's Tax Provision is fairly stable compared to the past year. Selling General Administrative is likely to climb to about 31.9 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 1.90 in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	216K	271K	6.8M	7.1M
Depreciation And Amortization	4.4K	8.4K	49K	51.5K

Interest Expense Depreciation And Amortization

NewAmsterdam Pharma fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Current Deferred Revenue
Total Assets		-0.83	0.79	0.91	1.0	0.69	-0.98	-0.75	0.89	1.0	0.77	0.83	1.0	0.56	0.03	0.8	0.93	1.0	0.78	-0.48	1.0	0.77	1.0	-0.83	0.77	0.99
Short Long Term Debt Total	-0.83		-0.8	-0.75	-0.83	-0.95	0.87	0.8	-0.93	-0.84	-0.45	-1.0	-0.84	-0.66	0.52	-0.94	-0.77	-0.82	-0.94	0.62	-0.84	-0.51	-0.85	1.0	-0.51	-0.8
Other Current Liab	0.79	-0.8		0.9	0.77	0.57	-0.88	-1.0	0.89	0.83	0.24	0.8	0.83	0.95	-0.1	0.61	0.89	0.77	0.59	-0.9	0.83	0.23	0.81	-0.8	0.23	0.81
Total Current Liabilities	0.91	-0.75	0.9		0.89	0.51	-0.93	-0.89	0.92	0.94	0.48	0.75	0.94	0.76	0.08	0.59	1.0	0.89	0.57	-0.61	0.94	0.47	0.93	-0.75	0.47	0.89
Total Stockholder Equity	1.0	-0.83	0.77	0.89		0.7	-0.98	-0.74	0.88	0.99	0.79	0.83	0.99	0.53	0.03	0.81	0.91	1.0	0.79	-0.46	0.99	0.79	1.0	-0.83	0.79	0.99
Property Plant And Equipment Net	0.69	-0.95	0.57	0.51	0.7		-0.71	-0.58	0.78	0.69	0.46	0.95	0.69	0.42	-0.67	0.98	0.54	0.69	0.98	-0.42	0.69	0.55	0.7	-0.95	0.55	0.65
Net Debt	-0.98	0.87	-0.88	-0.93	-0.98	-0.71		0.85	-0.93	-0.99	-0.66	-0.87	-0.99	-0.69	0.03	-0.8	-0.94	-0.98	-0.79	0.63	-0.99	-0.66	-0.99	0.87	-0.66	-0.99
Retained Earnings	-0.75	0.8	-1.0	-0.89	-0.74	-0.58	0.85		-0.9	-0.8	-0.17	-0.8	-0.8	-0.96	0.16	-0.59	-0.88	-0.73	-0.58	0.9	-0.8	-0.17	-0.78	0.8	-0.17	-0.77
Accounts Payable	0.89	-0.93	0.89	0.92	0.88	0.78	-0.93	-0.9		0.92	0.44	0.93	0.92	0.76	-0.3	0.8	0.93	0.87	0.8	-0.63	0.92	0.47	0.92	-0.93	0.47	0.85
Cash	1.0	-0.84	0.83	0.94	0.99	0.69	-0.99	-0.8	0.92		0.71	0.84	1.0	0.61	0.01	0.78	0.95	0.99	0.77	-0.52	1.0	0.72	1.0	-0.84	0.72	0.98
Non Current Assets Total	0.77	-0.45	0.24	0.48	0.79	0.46	-0.66	-0.17	0.44	0.71		0.45	0.71	-0.09	0.25	0.62	0.51	0.79	0.61	0.1	0.72	0.99	0.73	-0.45	0.99	0.75
Non Currrent Assets Other	0.83	-1.0	0.8	0.75	0.83	0.95	-0.87	-0.8	0.93	0.84	0.45		0.84	0.66	-0.52	0.95	0.76	0.82	0.94	-0.61	0.84	0.52	0.85	-1.0	0.52	0.79
Cash And Short Term Investments	1.0	-0.84	0.83	0.94	0.99	0.69	-0.99	-0.8	0.92	1.0	0.71	0.84		0.61	0.01	0.78	0.95	0.99	0.77	-0.52	1.0	0.72	1.0	-0.84	0.72	0.98
Common Stock Shares Outstanding	0.56	-0.66	0.95	0.76	0.53	0.42	-0.69	-0.96	0.76	0.61	-0.09	0.66	0.61		-0.16	0.4	0.75	0.53	0.39	-0.95	0.61	-0.09	0.59	-0.66	-0.09	0.59
Non Current Liabilities Total	0.03	0.52	-0.1	0.08	0.03	-0.67	0.03	0.16	-0.3	0.01	0.25	-0.52	0.01	-0.16		-0.51	0.06	0.05	-0.53	0.15	0.0	0.13	0.0	0.52	0.13	0.1
Other Current Assets	0.8	-0.94	0.61	0.59	0.81	0.98	-0.8	-0.59	0.8	0.78	0.62	0.95	0.78	0.4	-0.51		0.62	0.8	1.0	-0.41	0.79	0.69	0.8	-0.95	0.69	0.77
Total Liab	0.93	-0.77	0.89	1.0	0.91	0.54	-0.94	-0.88	0.93	0.95	0.51	0.76	0.95	0.75	0.06	0.62		0.91	0.6	-0.61	0.95	0.5	0.94	-0.76	0.5	0.91
Net Invested Capital	1.0	-0.82	0.77	0.89	1.0	0.69	-0.98	-0.73	0.87	0.99	0.79	0.82	0.99	0.53	0.05	0.8	0.91		0.78	-0.46	0.99	0.79	1.0	-0.81	0.79	0.99
Property Plant And Equipment Gross	0.78	-0.94	0.59	0.57	0.79	0.98	-0.79	-0.58	0.8	0.77	0.61	0.94	0.77	0.39	-0.53	1.0	0.6	0.78		-0.4	0.77	0.69	0.79	-0.94	0.69	0.75
Short Long Term Debt	-0.48	0.62	-0.9	-0.61	-0.46	-0.42	0.63	0.9	-0.63	-0.52	0.1	-0.61	-0.52	-0.95	0.15	-0.41	-0.61	-0.46	-0.4		-0.52	0.1	-0.51	0.61	0.1	-0.55
Total Current Assets	1.0	-0.84	0.83	0.94	0.99	0.69	-0.99	-0.8	0.92	1.0	0.72	0.84	1.0	0.61	0.0	0.79	0.95	0.99	0.77	-0.52		0.72	1.0	-0.84	0.72	0.98
Capital Stock	0.77	-0.51	0.23	0.47	0.79	0.55	-0.66	-0.17	0.47	0.72	0.99	0.52	0.72	-0.09	0.13	0.69	0.5	0.79	0.69	0.1	0.72		0.74	-0.52	1.0	0.75
Net Working Capital	1.0	-0.85	0.81	0.93	1.0	0.7	-0.99	-0.78	0.92	1.0	0.73	0.85	1.0	0.59	0.0	0.8	0.94	1.0	0.79	-0.51	1.0	0.74		-0.84	0.74	0.98
Short Term Debt	-0.83	1.0	-0.8	-0.75	-0.83	-0.95	0.87	0.8	-0.93	-0.84	-0.45	-1.0	-0.84	-0.66	0.52	-0.95	-0.76	-0.81	-0.94	0.61	-0.84	-0.52	-0.84		-0.52	-0.79
Common Stock	0.77	-0.51	0.23	0.47	0.79	0.55	-0.66	-0.17	0.47	0.72	0.99	0.52	0.72	-0.09	0.13	0.69	0.5	0.79	0.69	0.1	0.72	1.0	0.74	-0.52		0.75
Current Deferred Revenue	0.99	-0.8	0.81	0.89	0.99	0.65	-0.99	-0.77	0.85	0.98	0.75	0.79	0.98	0.59	0.1	0.77	0.91	0.99	0.75	-0.55	0.98	0.75	0.98	-0.79	0.75

Click cells to compare fundamentals

NewAmsterdam Pharma Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

NewAmsterdam Begin Period Cash Flow vs Ev To Free Cash Flow Analysis

Begin Period Cash Flow vs Ev To Free Cash Flow

Begin Period Cash Flow vs Ev To Free Cash Flow Correlation Analysis

Correlation Coefficient

Begin Period Cash Flow

Ev To Free Cash Flow

NewAmsterdam Pharma fundamental ratios Correlations

NewAmsterdam Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for NewAmsterdam Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets

Short Term Debt	- 1.0	Non Currrent Assets Other
Retained Earnings	- 1.0	Other Current Liab
Non Currrent Assets Other	- 1.0	Short Long Term Debt Total
Current Deferred Revenue	- 0.99	Net Debt
Net Working Capital	- 0.99	Net Debt
Total Current Assets	- 0.99	Net Debt